Media stories about Amicus Therapeutics (NASDAQ:FOLD) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amicus Therapeutics earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.7482306061469 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Notable Volatile Movements: Huntsman Corporation, (NYSE: HUN), Amicus Therapeutics, Inc., (NASDAQ: FOLD) – Global Export Lines (press release) (globalexportlines.com)
- After Hours Most Active for Mar 14, 2018 : QQQ, FOLD, F, MSFT, QEP, GM, USMC, BEN, CMCSA, BSX, CNP, EXEL – Nasdaq (nasdaq.com)
- Trending Stocks Analysis Report: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Iridium Communications Inc. (NASDAQ … – The Oracle Examiner (oracleexaminer.com)
- Are you searching Analysts Rated Stock: Amicus Therapeutics, Inc. (FOLD) – Wall Street Morning (wallstreetmorning.com)
- Zacks Investment Research Downgrades Amicus Therapeutics (FOLD) to Sell (americanbankingnews.com)
Shares of Amicus Therapeutics (NASDAQ:FOLD) traded up $0.01 on Wednesday, reaching $15.17. The company’s stock had a trading volume of 7,937,537 shares, compared to its average volume of 3,710,000. The firm has a market cap of $2,520.00, a P/E ratio of -18.06 and a beta of 1.59. Amicus Therapeutics has a 52-week low of $6.41 and a 52-week high of $17.40. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.60 and a quick ratio of 5.53.
A number of equities research analysts recently weighed in on the company. ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Robert W. Baird set a $20.00 price objective on Amicus Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Leerink Swann boosted their price objective on Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, January 15th. Finally, Cowen restated a “buy” rating and set a $22.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.06.
In other Amicus Therapeutics news, CEO John F. Crowley sold 65,581 shares of Amicus Therapeutics stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $13.51, for a total transaction of $885,999.31. Following the transaction, the chief executive officer now directly owns 393,076 shares of the company’s stock, valued at approximately $5,310,456.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Perceptive Advisors Llc bought 335,827 shares of the business’s stock in a transaction on Monday, March 5th. The shares were bought at an average cost of $13.56 per share, for a total transaction of $4,553,814.12. The disclosure for this purchase can be found here. Insiders have sold a total of 207,870 shares of company stock worth $3,066,112 over the last ninety days. Company insiders own 3.40% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://baseballnewssource.com/2018/03/14/amicus-therapeutics-fold-given-media-impact-score-of-0-19/1890457.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.